Law360, New York ( April 1, 2014, 5:13 PM EDT) -- In the last several years, drug and device manufacturers have pressed the U.S. Food and Drug Administration to clarify certain practices a manufacturer should follow when distributing truthful, nonmisleading scientific publications to health care professionals that may include information on unapproved new uses (i.e., "off-label uses") for an approved or cleared product. More recently, a number of manufacturers, in light of three high-profile court decisions that raise questions about the FDA's constitutional and statutory authority to regulate such manufacturer speech, have called upon the agency to undertake a comprehensive review of its regulatory approach to this area....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.